TB Manual

References

  1. World Health Organization. Strategy for the control and elimi- nation of tuberculosis. In: Implementing the WHO Stop TB Strategy: A Handbook for National Tuberculosis Control Programmes. Geneva: WHO Press;
  2. Cole B, Nilsen DM, Will L, Etkind SC, Burgos M, Chorba T. Essential Components of a Public Health Tuberculosis Prevention, Control, and Elimination Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis and the National Tuberculosis Controllers Association. MMWR Recomm Rep. 2020;69(7):1–27. doi:15585/mmwr.rr6907a1.
  3. Uplekar M, Weil D, Lonnroth K, et al. WHO’s new End TB The Lancet. 2015;385(9979):1799–1801. doi:10.1016/ S0140-6736(15)60570-0.
  4. World Health Organization. The End TB Strategy. https://www. int/tb/strategy/End_TB_Strategy.pdf. Published 2015. Accessed July 5, 2021.
  5. Australian Government Department of Health and Ageing. The strategic plan for control of tuberculosis in Australia: 2011–2015. Australian Government Department of Health and Ageing. health.gov.au. Accessed June 30, 2021.
  6. Degeling C, Carroll J, Denholm J, Marais B, Dawson Ending TB in Australia: Organizational challenges for regional tuberculosis programs. Health Policy. 2020;124(1):106–112. doi:10.1016/j. healthpol.2019.11.009.
  7. Public Health England. Collaborative TB Strategy for England, 2015 to 2020: end of programme 2015. GW-1954.
  8. Pan American Health Organization. The End TB Strategy: Main Indicators in the Americas.
  9. Kritski A, Barreira D, Junqueira-Kipnis AP, et al. Brazilian Response to Global End TB Strategy: The National Tuberculosis Research Agenda. Revista da Sociedade Brasileira de Medicina Tropical. 2016;49:135–145. doi:1590/0037-8682-0330-2015.
  10. Davidson EJ. Evaluative Reasoning. Methodological Briefs: Impact 2014;4:1–14.
  11. Coelho AA, Martiniano CS, Brito EWG, et al. Tuberculosis care: an evaluability study. Revista Latino-Americana de Enfermagem. 2014;22(5):792–800. doi:1590/0104-1169.3294.2482.
  12. Centers for Disease Control. Framework for Program Evaluation in Public MMWR. 1999;48(RR-11):1–40.
  13. Health Health Canada’s Strategy against Tuberculosis for First Nations on-Reserve. Ottawa, Ont.: Health Canada; 2012.
  14. Health Health Canada’s Monitoring and Performance Framework for Tuberculosis Programs for First Nations on-Reserve. Feb 12 2016.
  15. Pan-Canadian Public Health Guidance for Tuberculosis Prevention and Control Programs in Canada. 2013.
  16. Inuit Tapiriit Inuit Tuberculosis Elimination Framework. 2018.
  17. Haworth-Brockman M, Balakumar S, Head B, Keynan Y. Towards TB Elimination: Shared Priorities for TB Program Performance Measurement in Canada, a Proposal for Discussion. Winnipeg, Manitoba: National Collaborating Centre for Infectious Diseases; June 2019. 453.
  18. Cass A, Shaw T, Ehman M, Young J, Flood J, Royce S. Improved Outcomes Found After Implementing a Systematic Evaluation and Program Improvement Process for Public Health Reports.  1974-).  2013;128(5):367–376.  doi:10.1177/003335491312800507.
  19. Cavany SM, Sumner T, Vynnycky E, et al. An evaluation of tuberculosis contact investigations against national standards. Thorax. 2017;72(8):736–745. doi:1136/thoraxjnl-2016-209677.
  20. Government of Canada, Public Health Agency of Canada. Reported cases from 1924 to 2019 in Canada – Notifiable diseases on-line. https://diseases.canada.ca/notifiable/charts?c=pl. Published Updated Accessed January 1, 2000.
  21. Proceedings of the National Consensus Conference on December 3-5, 1997. 1998;24(Supplement 2):1-24.
  22. The global plan to stop TB 2006-2015: actions for life: towards a world free of tuberculosis. Geneva: Stop TB Partnership;
  23. Stewart The Delphi technique and judgmental forecasting. Clim Change. 1987;11(1-2):97–113. doi:10.1007/BF00138797.
  24. Niederberger M, Spranger J. Delphi Technique in Health Sciences: A Map. Front Public Health. 2020;8:457. doi:3389/ fpubh.2020.00457.
  25. von Schirnding Y. Health in Sustainable Development Planning: The Role of Indicators. Geneva: World Health Organization; 2002. WHO/HDE/HID/02.11.
  26. Langlois-Klassen D, Wooldrage KM, Manfreda J, et Piecing the puzzle together: foreign-born tuberculosis in an immigrant-receiving country. European Respiratory Journal. 2011;38(4):895–902. doi:10.1183/09031936.00196610.
  27. World Health Organization. Global Tuberculosis Control: surveil- lance, Planning, Financing. Geneva: WHO Press;
  28. Asadi L, Heffernan C, Menzies D, Long R. Effectiveness of Canada’s tuberculosis surveillance strategy in identifying im- migrants at risk of developing and transmitting tuberculosis: a population-based retrospective cohort The Lancet Public He a l t h . 2017;2(10):e450–e457.                do i: 10.1016/ S2468-2667(17)30161-5.
  29. Greenaway C, Pareek M, Chakra C-NA, et The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review. Eurosurveillance. 2018;23(14):17. doi:10.2807/1560-7917.ES.2018.23.14.17-00543.
  30. Berrocal-Almanza LC, Harris R, Lalor MK, et Effectiveness of pre-entry active tuberculosis and post-entry latent tuberculo- sis screening in new entrants to the UK: a retrospective, population-based cohort study. The Lancet Infectious Diseases. 2019;19(11):1191–1201. doi:10.1016/S1473-3099(19)30260-9.
  31. Kruijshaar ME, Abubakar I, Stagg HR, Pedrazzoli D, Lipman M. Migration and tuberculosis in the UK: targeting screening for latent infection to those at greatest risk of Thorax. 2013;68(12):1172–1174. doi:10.1136/thoraxjnl-2013-203254.
  32. Ehman M, Shaw T, Cass A, et al. Developing and Using Performance Measures Based on Surveillance Data for Program Improvement in Tuberculosis Journal of Public Health Management and  Practice.  2013;19(5):E29–E37.  doi:10.1097/PHH.0b013e3182751d6f.
  33. Stop TB Partnership, World Health The Global Plan to Stob TB 2011-2015: transforming the Fight towards Elimination of Tuberculosis. Geneva: World Health Organization; 2011.
  34. Horsburgh CR, Feldman S, Ridzon Practice Guidelines for the Treatment of Tuberculosis. Clinical Infectious Diseases. 2000;31(3):633–639. doi:10.1086/314007.
  35. Curtis E, Jones R, Tipene-Leach D, et al. Why cultural safety rath- er than cultural competency is required to achieve health equity: a literature review and recommended International Journal for Equity in Health. 2019;18(1):174. doi:10.1186/s12939-019-1082-3.
  36. Canadian Health Services Research Foundation. Performance Reporting to Help Organizations Promote Quality Improvement. Healthcare Policy | Politiques de Santé. 2008;4(2):70–74.
  37. Health Canada. Health Portfolio Sex and Gender-Based Analysis https://www.canada.ca/en/health-canada/corporate/trans- parency/corporate-management-reporting/heath-portfoli o-sex-gender-based-analysis-policy.html. Published 2017. Accessed July 27, 2021.
  38. World Health Organization. Closing data gaps in gender. https:// who.int/activities/improving-treatment-for-snakebite-patients. Published 2019. Accessed July 27, 2021.
  39. Global Health Data Exchange | GHDx. http://ghdx.healthdata. org/. Accessed July 27,
  40. Gigli Data Disaggregation: A Research Tool to Identify Health Inequities. Journal of Pediatric Health Care. 2021;35(3):332– 336. doi:10.1016/j.pedhc.2020.12.002.
  41. Gomes MGM, Barreto ML, Glaziou P, et End TB strategy: the need to reduce risk inequalities. BMC Infectious Diseases. 2016;16(1):132. doi:10.1186/s12879-016-1464-8.
  42. Smith A, Herington E, Loshak H. Tuberculosis Stigma and Racism, Colonialism, and Migration: A Rapid Qualitative Review. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health;
  43. Mathema B, Andrews JR, Cohen T, et al. Drivers of Tuberculosis J Infect Dis. 2017;216(suppl_6):S644–S653. doi:10.1093/infdis/jix354.
  44. Kwan CK, Ernst JD. HIV and Tuberculosis: a Deadly Human Clinical Microbiology Reviews. 2011;24(2):351–376. doi:10.1128/CMR.00042-10.
  45. Gupta KB, Gupta R, Atreja A, Verma M, Vishvkarma S. Tuberculosis and nutrition. Lung India: Official Organ of Indian Chest Society. 2009;26(1):9–16. doi:4103/0970-2113.45198.
  46. Sylla L, Bruce RD, Kamarulzaman A, Altice FL. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment ser- International Journal of Drug Policy. 2007;18(4):306–312. doi:10.1016/j.drugpo.2007.03.001.
  47. Zumla A, Malon P, Henderson J, Grange J. Impact of HIV infection on tuberculosis. Postgraduate Medical Journal. 2000;76(895):259–268. doi:1136/pmj.76.895.259.
  48. Marais BJ, Lönnroth K, Lawn SD, et Tuberculosis comorbidity with communicable and non-communicable diseases: inte- grating health services and control efforts. The Lancet Infectious Diseases . 2013;13(5):436–448.        doi: 10.1016/S1473- 3099(13)70015-X.
  49. Cormier M, Schwartzman K, N’Diaye DS, et al. Proximate de- terminants of tuberculosis in Indigenous peoples worldwide: a systematic The Lancet Global Health. 2019;7(1):e68–e80. doi:10.1016/S2214-109X(18)30435-2.
  50. Ali M. Treating tuberculosis as a social disease. The Lancet. 2014;383(9936):2195. doi:1016/S0140-6736(14)61063-1.
  51. Khan K, Rea E, McDermaid C, et al. Active Tuberculosis among Homeless Persons, Toronto, Ontario, Canada, 1998–2007. Emerging Infectious Diseases. 2011;17(3):357–365. doi:3201/eid1703.100833.
  52. Marks SM, Taylor Z, Burrows NR, Qayad MG, Miller B. Hospitalization of homeless persons with tuberculosis in the United Am. J. Public Health. 2000;90(3):435–438. doi:10.2105/ajph.90.3.435.
  53. Parriott A, Malekinejad M, Miller AP, Marks SM, Horvath H, Kahn Care Cascade for targeted tuberculosis testing and linkage to Care in Homeless Populations in the United States: a meta-analysis. BMC Public Health. 2018;18:485. doi:10.1186/ s12889-018-5393-x.
  54. Baker MA, Harries AD, Jeon CY, et The impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Medicine. 2011;9(1):81. doi:10.1186/1741-7015-9-81.
  55. Stevenson CR, Forouhi NG, Roglic G, et al. Diabetes and tubercu- losis: the impact of the diabetes epidemic on tuberculosis BMC Public Health. 2007;7(1):234. doi:10.1186/1471-2458-7-234.
  56. World Health Organization. Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs. Geneva: World Health Organization;
  57. Henderson DA. The challenge of eradication: lessons from past erad- ication Int J Tuberc Lung Dis. 1998;2(9 Suppl 1): S4–S8.
  58. World Health International Health Regulations. Geneva: WHO Press; 2005.
  59. Center for Disease Control. TB – National TB Program Objectives and Performance Targets for Centers for Disease Control and Prevention Web site. https://www.cdc.gov/tb/programs/evaluation/ indicators/default.htm. Published 2019. Accessed September 18, 2019.
  60. Bareja C, Waring J, Stapledon R, Toms C, Douglas P. Tuberculosis notifications in Australia. Commun Dis Intell. 2011;38(4):E356– 2014;
  61. Alaska Departement of Health and Social Services. Alaska Tuberculosis Program Manual.
  62. Minnesota Department of Health. Published 2021. https://www. state.mn.us/diseases/tb/stats/index.html. Accessed Jul 6, 2021.
  63. California Department of Public TB Performance Trends for National and California Objectives. 2016.
  64. Heffernan C, Long Would program performance indicators and a nationally coordinated response accelerate the elimination of tuberculosis in Canada? Can J Public Health. 2019;110(1):31–doi:10.17269/s41997-018-0106-x.
  65. Chan IHY, Kaushik N, Dobler CC. Post-migration follow-up of migrants identified to be at increased risk of developing tuberculosis at pre-migration screening: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2017;17(7):770–779. doi:1016/S1473-3099(17)30194-9.
  66. Long R, Asadi L, Heffernan C, et Is there a fundamental flaw in Canada’s post-arrival immigrant surveillance system for tuberculosis? PLOS One. 2019;14(3):e0212706. doi:10.1371/journal. pone.0212706.
  67. Ronald LA, Campbell JR, Rose C, et al. Estimated impact of World Health Organization latent tuberculosis screening guidelines in a region with a low tuberculosis incidence: retrospective cohort study. Clin Infect Dis. 2019;69(12):2101–2108. doi:1093/cid/ciz188.
  68. Long R, Ellis Public Health Agency of Canada, Canadian Lung Association, Canadian Thoracic Society. Canadian Tuberculosis Standards. 2007.
  69. Rutstein SE, Ananworanich J, Fidler S, et al. Clinical and public health implications of acute and early HIV detection and treatment: a scoping J Int AIDS Soc. 2017;20(1):21579. doi:10.7448/IAS.20.1.21579.
  70. Long R, Niruban S, Heffernan C, et A 10-year population based study of ‘opt-out’ HIV testing of tuberculosis patients in Alberta, Canada:  national  implications.  PLoS  One. 2014;9(6):e98993. doi:10.1371/journal.pone.0098993.
  71. Bogers SJ, Hulstein SH, Schim van der Loeff MF, et al. Current evidence on the adoption of indicator condition guided testing for HIV in western countries: A systematic review and meta-analysis. EClinicalMedicine. 2021;35:100877. doi:1016/j.eclinm.2021.100877.
  72. World Health Organization, UNAIDS, The Global Fund, PEPFAR. A Guide to Monitoring and Evaluation for Collaborative TB/HIV Activities-2015 Revisions. Geneva: WHO Press;
  73. Canadian Medical Association. Guidelines for the identification, investigation and treatment of individuals with concomitant tu- berculosis and HIV infection. Bureau of Communicable Disease Epidemiology, Canada Department of National Health and CMAJ. 1993;148(11):1963–1970.
  74. Long R, Houston S, Hershfield E. Canadian Tuberculosis Committee of the Centre for Infectious Disease P, Control P, Public Health Branch HC. Recommendations for screening and prevention of tuberculosis in patients with HIV and for screening for HIV in patients with tuberculosis and their contacts. CMAJ. 2003;169(8):789–791.
  75. Haworth-Brockman MJ, Keynan Y. Strengthening tuberculosis surveillance in Canada. CMAJ. 2019;191(26):E743–E744. doi:1503/cmaj.72225.
  76. Migliori GB, Nardell E, Yedilbayev A, et Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional  Office  for  Europe.  Eur  Respir  J. 2019;53(6):1900391. doi:10.1183/13993003.00391-2019.
  77. Golub JE, Bur S, Cronin WA, et al. Delayed tuberculosis diagnosis and tuberculosis transmission. The International Journal of Tuberculosis and Lung Disease. 2006;10(1):24–30.
  78. Mitchison DA. Infectivity of patients with pulmonary tuberculosis during Eur Respir J. 1990;3(4):385–386.
  79. LaFreniere M, Dam D, Strudwick L, McDermott S. Tuberculosis drug resistance in Canada: 2018. Can Commun Dis Rep. 2020;46(1):9–15. doi:14745/ccdr.v46i01a02.
  80. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet (London, England). 2002;360(9332):528–534.
  81. Calderwood CJ, Wilson JP, Fielding KL, et Dynamics of sputum conversion during effective tuberculosis treatment: A systematic review  and  meta-analysis.  PLOS  Med . 2021;18(4):e1003566. doi:10.1371/journal.pmed.1003566.
  82. World Health Organization. 8 TUBERCULOSIS CONTROL PROGRAMME. 1991.
  83. Hargreaves JR, Boccia D, Evans CA, Adato M, Petticrew M, Porter JDH. The Social Determinants of Tuberculosis: From Evidence to Am. J. Public Health. 2011;101(4):654–662. doi:10.2105/AJPH.2010.199505.
  84. Veen J. Microepidemics of tuberculosis: the stone-in-the-pond Tuber Lung Dis. 1992;73(2):73–76. doi:10.1016/ 0962-8479(92)90058-R.
  85. Fox GJ, Dobler CC, Marks GB. Active case finding in contacts of people with tuberculosis. The Cochrane Database of Systematic Reviews. 2011;(9):CD008477. doi:1002/14651858.CD008477.pub2.
  86. National Tuberculosis Controllers A, Centers for Disease C, Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005;54(RR-15):1–47.
  87. Luzzati R, Migliori GB, Zignol M, et Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. Eur Respir J. 2017;50(5):1701414. doi:10.1183/1399300 3.01414-2017.
  88. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human  immunodeficiency    An  analysis  using restriction-fragment-length polymorphisms. The New England Journal  of  Medicine.  1992;326(4):231–235.  doi:10.1056/ NEJM199201233260404.
  89. Canada PHAo. Chapter 12: Canadian Tuberculosis Standards 7th Edition: 2014 – Contact follow-up and outbreak management in Tuberculosis control. Published 2014. https://www.canada.ca/ en/public-health/services/infectious-diseases/canadian-tuberculosi s-standards-7th-edition/edition-8.html. Accessed February 17,
  90. Ai J-W, Ruan Q-L, Liu Q-H, Zhang W-H. Updates on the risk factors for latent tuberculosis reactivation and their Emerging Microbes Infect. 2016;5(2):e10. doi:10.1038/ emi.2016.10.
  91. Fox GJ, Dobler CC, Marais BJ, Denholm Preventive therapy for latent tuberculosis infection—the promise and the challenges. International Journal of Infectious Diseases. 2017;56:68–76. doi:10.1016/j.ijid.2016.11.006.
  92. Rangaka MX, Cavalcante SC, Marais BJ, et al. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculo- sis Lancet. 2015;386(10010):2344–2353. doi:10.1016/S0140-6736(15)00323-2.
  93. Dobler CC, Martin A, Marks GB. Benefit of treatment of latent tuberculosis infection in individual European Respiratory Journal. 2015;46(5):1397–1406. doi:10.1183/ 13993003.00577-2015.
  94. Kim HW, Kim Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy. Tuberculosis and Respiratory Diseases. 2018;81(1):6–12. doi:10.4046/trd.2017.0052.
  95. Comstock GW, Edwards The competing risks of tuberculosis and hepatitis for adult tuberculin reactors. Am Rev Respir Dis. 1975;111(5):573–577. doi:10.1164/arrd.1975.111.5.573.
  96. Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in N  Engl  J  Med.  2018;379(5):440–453.  doi:10.1056/NEJMoa1714283.
  97. Macaraig MM, Jalees M, Lam C, Burzynski J. Improved treatment completion with shorter treatment regimens for latent tuberculous Int  j  Tuberc  Lung  Dis.  2018;22(11):1344–1349. doi:10.5588/ijtld.18.0035.
  98. Ferebee SH, Mount FW. Tuberculosis Morbidity in a Controlled Trial of the Prophylactic Use of Isoniazid among Household American  Review  of  Respiratory  Disease. 1962;85(4):490–510.
  99. Molhave M, Wejse Historical review of studies on the effect of treating latent tuberculosis. Int J Infect Dis. 2020;92S:S31–S36. doi:10.1016/j.ijid.2020.03.011.

Switch To: Français

Previously
Funding
Up Next
Appendix 1: Monitoring tuberculosis program performance